MAPT and Parkinson disease: A small open-label phase I clinical trial in patients with PD dementia and DLB showed positive safety and tolerability profiles [88] and phase II randomized-controlled trial confirmed reasonable drug safety and demonstrated effects on CSF levels of dopamine metabolites, α-synuclein oligomers, and tau in patients with PD [89].